- Home
- FBRX vs CLNN Comparison
FBRX vs CLNN Comparison
Compare FBRX & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- CLNN
- Stock Information
- Founded
- FBRX N/A
- CLNN 2012
- Country
- FBRX United States
- CLNN United States
- Employees
- FBRX N/A
- CLNN N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- CLNN Health Care
- Exchange
- FBRX Nasdaq
- CLNN Nasdaq
- Market Cap
- FBRX 35.3M
- CLNN 35.9M
- IPO Year
- FBRX N/A
- CLNN N/A
- Fundamental
- Price
- FBRX $7.35
- CLNN $3.11
- Analyst Decision
- FBRX Strong Buy
- CLNN Strong Buy
- Analyst Count
- FBRX 4
- CLNN 4
- Target Price
- FBRX $76.58
- CLNN $55.25
- AVG Volume (30 Days)
- FBRX 54.6K
- CLNN 52.8K
- Earning Date
- FBRX 05-12-2025
- CLNN 05-07-2025
- Dividend Yield
- FBRX N/A
- CLNN N/A
- EPS Growth
- FBRX N/A
- CLNN N/A
- EPS
- FBRX N/A
- CLNN N/A
- Revenue
- FBRX N/A
- CLNN $342,000.00
- Revenue This Year
- FBRX N/A
- CLNN N/A
- Revenue Next Year
- FBRX N/A
- CLNN $17,399.78
- P/E Ratio
- FBRX N/A
- CLNN N/A
- Revenue Growth
- FBRX N/A
- CLNN N/A
- 52 Week Low
- FBRX $4.11
- CLNN $2.57
- 52 Week High
- FBRX $28.68
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- FBRX 44.84
- CLNN 34.57
- Support Level
- FBRX $7.10
- CLNN $2.57
- Resistance Level
- FBRX $9.04
- CLNN $4.66
- Average True Range (ATR)
- FBRX 1.32
- CLNN 0.33
- MACD
- FBRX 0.34
- CLNN -0.13
- Stochastic Oscillator
- FBRX 50.62
- CLNN 25.60
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).